Construction and characterization of the double unmarked Mycobacterium tuberculosis mutant sigE/fadD26 as a vaccine candidate.
Despite the great increase of the understanding of the biology and pathogenesis of Mycobacterium tuberculosis achieved by the scientific community in the last decades, tuberculosis (TB) still represents one of the major threats for human global health. The only available vaccine (Mycobacterium bovis BCG) protects children from disseminated forms of TB, but does not effectively protect adults from the respiratory form of the disease, making the development of new and more efficacious vaccines against the pulmonary forms of TB a major goal to improve global health. Among the different strategies being developed to reach this goal is that to construct attenuated strains more efficacious and safer than BCG. We recently showed that a sigE mutant of M. tuberculosis was more attenuated and more efficacious than BCG in a mouse model of infection. In this paper, we describe the construction and characterization of an unmarked double sigE/fadD26 M. tuberculosis mutant fulfilling the criteria of the Geneva consensus to enter human clinical trials. Presented data suggest that this mutant is even more attenuated and slightly more efficacious than the previous sigE mutant in different mouse models of infection, and equivalent to BCG in a Guinea pig model of infection.